CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing
CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, today announced an additional $38 million closing of its Series B financing. This additional investment brings the total Series B financing round to nearly $140 million. The previous Series B investment was led by Vertex Pharmaceuticals and Bayer Global Investments, an affiliate of Bayer AG, as part of the company’s strategic investment in CRISPR Therapeutics. This second, oversubscribed closing of the Series B financing, includes several new institutional investors and specialized healthcare funds. Participating investors in this round include Franklin Templeton Investments, New Leaf Venture Partners, funds advised by Clough Capital Partners L.P. and Wellington Capital Management L.L.P., and other undisclosed funds specializing in life sciences.
“We are very pleased to add these top tier institutional investors in the most recent closing of our Series B financing,” commented Dr. Rodger Novak, Chief Executive Officer of CRISPR Therapeutics. “Along with the recent investments made by our strategic partners, Vertex and Bayer, we believe this further investment represents a strong validation of our approach to translate the novel CRISPR/Cas9 gene-editing technology into life-changing medicines for patients. We plan to use these proceeds to advance our current and future programs to the clinic and to expand our research and development organization in Cambridge, Massachusetts.”
Guggenheim Securities acted as financial advisor to CRISPR Therapeutics, while Vischer AG and Goodwin Procter acted as legal counsel to CRISPR Therapeutics on this transaction.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the Company’s scientific founder Emmanuelle Charpentier, Ph.D., who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com .
Westwicke Partners for CRISPR Therapeutics
Chris Brinzey, 339-970-2843
W2O Group for CRISPR Therapeutics
Jennifer Paganelli, 347-658-8290
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
TAKEDA15.12.2017 13:36 | pressemeddelelse
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
TWISPAY15.12.2017 13:23 | pressemeddelelse
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards
PEACE-FORUM15.12.2017 12:40 | pressemeddelelse
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum
CA-KENNEDY-WILSON15.12.2017 12:02 | pressemeddelelse
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million
NV-NAC-FOUNDATION15.12.2017 10:02 | pressemeddelelse
AML BitCoin Enters Phase II of ICO
THE-CITY-OF-JOENSUU15.12.2017 09:26 | pressemeddelelse
Joensuu City Challenge – International Competition for Innovative SMEs Opened
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum